This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Tamoxifen Pharmacogenetics and Clinical Effects

This study has been completed.
Indiana University School of Medicine
Information provided by:
National Institute of General Medical Sciences (NIGMS) Identifier:
First received: September 27, 2005
Last updated: September 24, 2008
Last verified: November 2007
The purpose of this research is to try to identify which women who take tamoxifen are likely to suffer from hot flashes or are more likely to have other side effects or benefits from the drug. The researchers will do so by determining whether there are mutations that normally occur in human DNA that might influence the way individuals respond to medications.

Condition Intervention Phase
Breast Cancer Drug: Tamoxifen (pharmacodynamic analysis) Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Pilot Trial Correlating Metabolic Profile of Tamoxifen With Pharmacogenetic Predictors and Clinical Effects

Resource links provided by NLM:

Further study details as provided by National Institute of General Medical Sciences (NIGMS):

Biospecimen Retention:   Samples With DNA
Whole Blood Serum Plasma

Enrollment: 297
Study Start Date: September 2002
Study Completion Date: August 2007
Intervention Details:
    Drug: Tamoxifen (pharmacodynamic analysis)
    Tamoxifen 20mg po daily
Detailed Description:

The study will test the following hypotheses.

  1. There is a relationship between genetically distinct metabolic profiles of tamoxifen and the frequency and severity of hot flashes in women on chronic tamoxifen therapy.
  2. Genetically distinct metabolic profiles for tamoxifen effect lipid profile, bone turnover metabolites and bone mineral density, and coagulation factors.
  3. Different genetic profiles of estrogen responsive genes influence the pharmacodynamic effects of tamoxifen in cardiovascular system.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Eligible patients included women 18 years or older, non-pregnant or lactating, who were recommended tamoxifen for adjuvant treatment or for the prevention of breast cancer from the oncology clinics.

Inclusion Criteria:

  1. 18-years or older
  2. Women with a prior breast cancer or who are at a high risk for developing the disease and about to start tamoxifen therapy.
  3. Participants must not be treated with concomitant chemotherapy or hormone therapy other than tamoxifen. They must not have ovarian ablation or currently being treated with radiation therapy and/or chronic corticosteroids.
  4. The participant must not be taking anti-hot flash therapy (clonidine, bellergal, megestrol acetate). Vitamin E, selective serotonin reuptake inhibitors, or herbal remedies are allowed provided that the participant has been taking the remedy for at least 4 weeks and intends to continue the remedy for at least the first month while on the study, and allows for one-month follow up evaluation (hot flash diaries and blood samples).
  5. The participant must not be pregnant or lactating.
  6. The participant is able and willing to sign an informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00228930

United States, Indiana
Indiana University
Indianapolis, Indiana, United States, 46202
United States, Michigan
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
National Institute of General Medical Sciences (NIGMS)
Indiana University School of Medicine
Principal Investigator: David Flockhart, MD, PhD Indiana University School of Medicine
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00228930     History of Changes
Other Study ID Numbers: 0208-14
U01GM061373-05 ( U.S. NIH Grant/Contract )
Study First Received: September 27, 2005
Last Updated: September 24, 2008

Keywords provided by National Institute of General Medical Sciences (NIGMS):
Breast Cancer

Additional relevant MeSH terms:
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Bone Density Conservation Agents processed this record on August 22, 2017